Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SOLIGENIX, INC. Director's Dealing 2009

Mar 30, 2009

35119_dirs_2009-03-30_024702a7-ce14-48a3-924a-f68db82767e8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DOR BIOPHARMA INC (DORB)
CIK: 0000812796
Period of Report: 2009-03-27

Reporting Person: Brey Robert N (Chief Scientific Officer/SrVP)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2000-02-08 Stock Options (Right to Buy) $3.94 A 9000 Acquired 2010-02-07 Common Stock (9000) Direct
2006-05-10 Stock Options (Right to Buy) $.33 A 600000 Acquired 2016-05-09 Common Stock (600000) Direct
2007-08-10 Stock Options (Right to Buy) $.47 A 200000 Acquired 2017-08-09 Common Stock (200000) Direct
2008-12-18 Stock Options (Right to Buy) $.06 A 800000 Acquired 2018-12-17 Common Stock (800000) Direct

Footnotes

F1: Granted stock options to purchase 9,000 shares of the Company's common stock that vested immediately. The exercise price of the options equals $3.94 per share, the market price of the
Company s common stock as of the close of business on February 8, 2000.

F2: Granted stock options to purchase 600,000 shares of the Company's common stock, of which 150,000 shares vest immediately and the remainder of the options will vest on each three (3) month anniversary of the grant date at a rate of 37,500 options per quarter. The exercise price of the options equals $0.33 per share, the market price of the
Company s common stock as of the close of business on May 10, 2006.

F3: Granted stock options to purchase 200,000 shares of the Company's common stock, of which 50,000 shares vest immediately and the remainder of the options will vest on each three (3) month anniversary of the grant date at a rate of 12,500 options per quarter. The exercise price of the options equals $0.47 per share, the market price of the Company's common stock as of the close of business on August 10, 2007.

F4: Granted stock options to purchase 800,000 shares of the Company's common stock, of which 200,000 shares vest immediately and the remainder of the options will vest on each three (3) month anniversary of the grant date at a rate of 50,000 options per quarter. The exercise price of the options equals $0.06 per share, the market price of the Company's common stock as of the close of business on December 18, 2008.